Sequoia Financial Advisors LLC Purchases Shares of 2,424 ICU Medical, Inc. (NASDAQ:ICUI)

Sequoia Financial Advisors LLC acquired a new stake in ICU Medical, Inc. (NASDAQ:ICUI) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,424 shares of the medical instruments supplier’s stock, valued at approximately $442,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Everence Capital Management Inc. bought a new position in shares of ICU Medical during the third quarter valued at $536,000. OLD National Bancorp IN bought a new position in ICU Medical during the 3rd quarter valued at about $218,000. Creative Planning lifted its holdings in ICU Medical by 58.6% during the 3rd quarter. Creative Planning now owns 6,193 shares of the medical instruments supplier’s stock valued at $1,128,000 after purchasing an additional 2,287 shares during the last quarter. Hexagon Capital Partners LLC boosted its position in ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 122 shares in the last quarter. Finally, Diversified Trust Co bought a new stake in ICU Medical during the third quarter worth about $455,000. 96.10% of the stock is owned by institutional investors.

ICU Medical Stock Up 0.0 %

Shares of NASDAQ ICUI opened at $175.56 on Monday. The firm’s 50-day moving average is $172.59 and its 200-day moving average is $135.13. ICU Medical, Inc. has a 1 year low of $78.28 and a 1 year high of $188.53. The firm has a market capitalization of $4.28 billion, a PE ratio of -71.66 and a beta of 0.66. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. The company had revenue of $596.50 million for the quarter, compared to the consensus estimate of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.58 EPS. Equities analysts expect that ICU Medical, Inc. will post 3.81 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. KeyCorp lifted their target price on shares of ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Thursday, October 10th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Raymond James increased their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Finally, Jefferies Financial Group started coverage on shares of ICU Medical in a research report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, ICU Medical currently has an average rating of “Moderate Buy” and an average target price of $170.25.

Insider Activity at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,320,691.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,552 shares of company stock worth $6,679,322. 6.70% of the stock is currently owned by company insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.